photo-1783961494952.jpg
Provide 10 drug interactions for the above form to be filled complete information
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Now I have enough authoritative information to fill out 10 complete Pharmacist Intervention Reporting & Documentation Forms. Here they are:
FAROOQIA COLLEGE OF PHARMACY
Department of Clinical Pharmacy
Pharmacist Intervention Reporting & Documentation Form
FORM 1
Hospital: CSI HMH | Intervention Date: 13/07/2026
| Field | Details |
|---|---|
| Patient Name | Mr. Rajesh Kumar |
| Age | 62 years |
| Date of Admission | 12/07/2026 |
| IP/OP No | IP/2026/1001 |
| Weight (Kg) | 72 kg |
| Gender | Male |
| Unit | Cardiology |
Reason for Admission/Visit C/O: Atrial fibrillation, on chronic warfarin therapy; admitted for persistent INR elevation (INR = 4.8) with gum bleeding
Drug Related Problem(s) Identified: Drug-Drug Interaction - Warfarin + Fluconazole. Fluconazole stereoselectively inhibits CYP2C9-mediated metabolism of S-warfarin (the more potent enantiomer), causing warfarin accumulation and supratherapeutic INR.
Reason(s) for Intervention: Patient prescribed fluconazole 150 mg for oral candidiasis 5 days ago without warfarin dose adjustment. INR rose from 2.4 to 4.8. Risk of major bleeding (intracranial, GI hemorrhage).
Suggestions Made: (1) Withhold warfarin for 1-2 doses. (2) Switch antifungal to topical nystatin if possible. (3) Monitor INR daily until stable. (4) Reduce warfarin dose by 25-30% if fluconazole must be continued. (5) Educate patient on signs of bleeding.
| Informed to HCP? | [X] Yes |
| Accepted? | [X] Yes |
| If No? Give Reasons: | - |
| Name & Signature of HCP | Dr. Suresh Nair, Cardiologist |
| Name & Signature of Pharmacist | [Clinical Pharmacist, Dept. of Clinical Pharmacy] |
Preceptor's Name & Signature: _______________
FORM 2
Hospital: BHIO | Intervention Date: 13/07/2026
| Field | Details |
|---|---|
| Patient Name | Mrs. Fatima Begum |
| Age | 55 years |
| Date of Admission | 11/07/2026 |
| IP/OP No | IP/2026/1002 |
| Weight (Kg) | 65 kg |
| Gender | Female |
| Unit | General Medicine |
Reason for Admission/Visit C/O: Type 2 diabetes mellitus on metformin; admitted with symptomatic hypoglycemia after being started on fluoxetine (SSRI) for depression
Drug Related Problem(s) Identified: Drug-Drug Interaction - Metformin + Fluoxetine (SSRI). SSRIs can produce pharmacodynamic interactions enhancing insulin sensitivity and altering glucose homeostasis. Fluoxetine independently lowers blood glucose and potentiates the glucose-lowering effect of antidiabetic agents.
Reason(s) for Intervention: Blood glucose dropped to 52 mg/dL. Patient did not receive counseling about hypoglycemia risk when fluoxetine was added to existing metformin regimen. SSRIs produce pharmacokinetic interactions via CYP enzyme inhibition and pharmacodynamic hypoglycemic effects.
Suggestions Made: (1) Reduce metformin dose temporarily while fluoxetine is being titrated. (2) Increase blood glucose monitoring frequency (4x/day). (3) Educate patient on hypoglycemic symptoms and corrective measures. (4) Coordinate endocrinology and psychiatry review. (5) Consider switching to an SSRI with lesser metabolic impact if glycemic control remains poor.
| Informed to HCP? | [X] Yes |
| Accepted? | [X] Yes |
| If No? Give Reasons: | - |
| Name & Signature of HCP | Dr. Anita Sharma, Gen. Medicine |
| Name & Signature of Pharmacist | [Clinical Pharmacist] |
Preceptor's Name & Signature: _______________
FORM 3
Hospital: BMH | Intervention Date: 13/07/2026
| Field | Details |
|---|---|
| Patient Name | Mr. Srinivas Reddy |
| Age | 68 years |
| Date of Admission | 10/07/2026 |
| IP/OP No | IP/2026/1003 |
| Weight (Kg) | 80 kg |
| Gender | Male |
| Unit | Cardiology |
Reason for Admission/Visit C/O: Post-MI on aspirin 75 mg/day; prescribed ibuprofen 400 mg TID for knee osteoarthritis by a different physician
Drug Related Problem(s) Identified: Drug-Drug Interaction - Aspirin + Ibuprofen (NSAID). Ibuprofen administered multiple times daily competitively inhibits aspirin's irreversible acetylation of platelet COX-1 by occupying the active site first, thereby undermining aspirin's cardioprotective antiplatelet effect.
Reason(s) for Intervention: Patient is at high cardiovascular risk (post-MI). Ibuprofen taken 3x/day blocks aspirin's cardioprotective platelet inhibition. This interaction may increase risk of recurrent MI or cardiovascular events.
Suggestions Made: (1) Discontinue ibuprofen immediately. (2) Switch to acetaminophen (paracetamol) 500-1000 mg TID for knee pain (does not interfere with aspirin's COX-1 pathway). (3) If NSAID is unavoidable, advise patient to take aspirin at least 2 hours before ibuprofen. (4) Consider topical diclofenac gel as a local option. (5) Refer to physiotherapy for osteoarthritis management.
| Informed to HCP? | [X] Yes |
| Accepted? | [X] Yes |
| If No? Give Reasons: | - |
| Name & Signature of HCP | Dr. Praveen Rao, Cardiologist |
| Name & Signature of Pharmacist | [Clinical Pharmacist] |
Preceptor's Name & Signature: _______________
FORM 4
Hospital: CSI HMH | Intervention Date: 13/07/2026
| Field | Details |
|---|---|
| Patient Name | Mr. Venkatesh Murthy |
| Age | 74 years |
| Date of Admission | 09/07/2026 |
| IP/OP No | IP/2026/1004 |
| Weight (Kg) | 60 kg |
| Gender | Male |
| Unit | Neurology |
Reason for Admission/Visit C/O: Epilepsy on phenobarbital (barbiturate); admitted for pulmonary tuberculosis; rifampin added to anti-TB regimen
Drug Related Problem(s) Identified: Drug-Drug Interaction - Warfarin + Rifampin AND Phenobarbital + Rifampin. Both barbiturates and rifampin cause marked induction of hepatic CYP enzymes (CYP2C9, CYP3A4) that metabolize warfarin and many other drugs, dramatically reducing plasma drug concentrations and therapeutic effect.
Reason(s) for Intervention: Patient is also on warfarin for DVT. Co-administration of rifampin + phenobarbital produces additive/synergistic hepatic enzyme induction, causing a marked decrease in warfarin anticoagulant effect and sub-therapeutic phenobarbital levels, risking seizure breakthrough.
Suggestions Made: (1) Monitor INR closely - expect significantly reduced INR; warfarin dose may need to be doubled or tripled. (2) Monitor phenobarbital serum levels; dose adjustment likely needed. (3) Alert treating physician regarding this triple drug interaction risk. (4) When TB treatment ends, reduce doses gradually to avoid over-anticoagulation/toxicity. (5) Consider alternative anti-TB regimen if clinically appropriate.
| Informed to HCP? | [X] Yes |
| Accepted? | [X] Yes |
| If No? Give Reasons: | - |
| Name & Signature of HCP | Dr. Kiran Kumar, Neurologist |
| Name & Signature of Pharmacist | [Clinical Pharmacist] |
Preceptor's Name & Signature: _______________
FORM 5
Hospital: BHIO | Intervention Date: 13/07/2026
| Field | Details |
|---|---|
| Patient Name | Ms. Divya Patel |
| Age | 34 years |
| Date of Admission | 13/07/2026 |
| IP/OP No | OP/2026/1005 |
| Weight (Kg) | 58 kg |
| Gender | Female |
| Unit | Psychiatry / OPD |
Reason for Admission/Visit C/O: Depression on sertraline (SSRI); prescribed tramadol for low back pain at OPD visit
Drug Related Problem(s) Identified: Drug-Drug Interaction - SSRI (Sertraline) + Tramadol. Risk of Serotonin Syndrome. Tramadol inhibits serotonin and norepinephrine reuptake; combined with an SSRI, serotonergic excess can occur. Additionally, SSRIs via CYP2D6 inhibition can impair tramadol's conversion to active M1 metabolite, altering its analgesic efficacy.
Reason(s) for Intervention: This combination may precipitate serotonin syndrome (hyperthermia, agitation, myoclonus, diaphoresis, tremor) which is potentially life-threatening. Risk is especially significant at higher tramadol doses.
Suggestions Made: (1) Avoid tramadol in patients on SSRIs if possible. (2) Switch to acetaminophen, NSAIDs, or if opioid is necessary, consider morphine or oxycodone (lower serotonergic risk). (3) If tramadol is unavoidable, use the lowest effective dose with close monitoring. (4) Counsel patient on serotonin syndrome symptoms - instruct to seek emergency care if symptoms develop. (5) Document in patient's allergy/interaction record.
| Informed to HCP? | [X] Yes |
| Accepted? | [X] Yes |
| If No? Give Reasons: | - |
| Name & Signature of HCP | Dr. Meena Iyer, Psychiatrist |
| Name & Signature of Pharmacist | [Clinical Pharmacist] |
Preceptor's Name & Signature: _______________
FORM 6
Hospital: BMH | Intervention Date: 13/07/2026
| Field | Details |
|---|---|
| Patient Name | Mr. Harish Gowda |
| Age | 58 years |
| Date of Admission | 08/07/2026 |
| IP/OP No | IP/2026/1006 |
| Weight (Kg) | 78 kg |
| Gender | Male |
| Unit | Nephrology |
Reason for Admission/Visit C/O: Chronic kidney disease (CKD Stage 3) on ACE inhibitor (enalapril); admitted with hyperkalemia (K+ = 6.4 mEq/L) after being prescribed spironolactone for resistant hypertension
Drug Related Problem(s) Identified: Drug-Drug Interaction - ACE Inhibitor (Enalapril) + Spironolactone (Potassium-sparing diuretic). Both drugs independently reduce potassium excretion. ACE inhibitors reduce aldosterone secretion; spironolactone is an aldosterone antagonist. Co-administration causes additive hyperkalemia, particularly dangerous in CKD where renal potassium excretion is already impaired.
Reason(s) for Intervention: Patient developed severe hyperkalemia (K+ 6.4 mEq/L) with ECG changes (peaked T waves). This combination requires extreme caution in CKD patients and regular potassium monitoring.
Suggestions Made: (1) Withhold spironolactone temporarily until K+ normalized. (2) Administer calcium gluconate IV for cardioprotection. (3) Consider sodium-glucose co-transporter inhibitor (SGLT2i) or amlodipine as alternative for resistant hypertension. (4) If spironolactone is restarted, use the lowest possible dose with weekly K+ monitoring for the first month. (5) Restrict dietary potassium intake.
| Informed to HCP? | [X] Yes |
| Accepted? | [X] Yes |
| If No? Give Reasons: | - |
| Name & Signature of HCP | Dr. Sunil Shetty, Nephrologist |
| Name & Signature of Pharmacist | [Clinical Pharmacist] |
Preceptor's Name & Signature: _______________
FORM 7
Hospital: CSI HMH | Intervention Date: 13/07/2026
| Field | Details |
|---|---|
| Patient Name | Mr. Abdul Raheem |
| Age | 65 years |
| Date of Admission | 07/07/2026 |
| IP/OP No | IP/2026/1007 |
| Weight (Kg) | 82 kg |
| Gender | Male |
| Unit | Cardiology |
Reason for Admission/Visit C/O: Cardiac arrhythmia on amiodarone; warfarin for atrial fibrillation; admitted with INR of 5.6 and hematuria
Drug Related Problem(s) Identified: Drug-Drug Interaction - Amiodarone + Warfarin. Amiodarone inhibits the CYP2C9-mediated metabolism of both R- and S-warfarin enantiomers (non-stereoselective), dramatically increasing warfarin plasma levels and anticoagulant effect. This interaction can persist for weeks to months after amiodarone discontinuation due to its extremely long half-life (40-55 days).
Reason(s) for Intervention: INR elevated to 5.6 with active hematuria. Amiodarone was initiated 3 weeks ago without corresponding warfarin dose reduction. This is a well-known, serious, and predictable interaction listed in standard pharmacology references.
Suggestions Made: (1) Hold warfarin until INR returns to therapeutic range (2-3). (2) Reduce warfarin maintenance dose by 30-50% once amiodarone is continued long-term. (3) Increase INR monitoring frequency: weekly for first 1-2 months, then every 2 weeks. (4) Investigate and manage hematuria. (5) Maintain patient education log documenting the interaction.
| Informed to HCP? | [X] Yes |
| Accepted? | [X] Yes |
| If No? Give Reasons: | - |
| Name & Signature of HCP | Dr. Deepak Menon, Cardiologist |
| Name & Signature of Pharmacist | [Clinical Pharmacist] |
Preceptor's Name & Signature: _______________
FORM 8
Hospital: BHIO | Intervention Date: 13/07/2026
| Field | Details |
|---|---|
| Patient Name | Mrs. Savitha Rao |
| Age | 45 years |
| Date of Admission | 12/07/2026 |
| IP/OP No | OP/2026/1008 |
| Weight (Kg) | 62 kg |
| Gender | Female |
| Unit | Endocrinology OPD |
Reason for Admission/Visit C/O: Hypothyroidism on levothyroxine; prescribed cholestyramine (bile acid sequestrant) for hypercholesterolemia at the same OPD visit
Drug Related Problem(s) Identified: Drug-Drug Interaction - Levothyroxine + Cholestyramine. Cholestyramine is a non-absorbable anion-exchange resin that binds levothyroxine in the intestine, reducing its absorption and bioavailability. This same mechanism applies to warfarin as well - cholestyramine binds warfarin in the intestine, reducing absorption. The patient risks hypothyroidism relapse.
Reason(s) for Intervention: Both medications were prescribed to be taken in the morning without timing guidance. Co-administration causes significant reduction in levothyroxine bioavailability, leading to sub-therapeutic thyroid hormone levels and hypothyroid symptoms (fatigue, weight gain, cold intolerance).
Suggestions Made: (1) Separate administration - take levothyroxine at least 4-6 hours before or after cholestyramine. (2) Monitor TSH levels 6-8 weeks after starting cholestyramine to detect any need for levothyroxine dose adjustment. (3) Counsel patient about the importance of the dosing interval. (4) Consider statin therapy (e.g., atorvastatin) as an alternative that does not interfere with levothyroxine absorption. (5) Document interaction in medication record.
| Informed to HCP? | [X] Yes |
| Accepted? | [X] Yes |
| If No? Give Reasons: | - |
| Name & Signature of HCP | Dr. Lakshmi Prasad, Endocrinologist |
| Name & Signature of Pharmacist | [Clinical Pharmacist] |
Preceptor's Name & Signature: _______________
FORM 9
Hospital: BMH | Intervention Date: 13/07/2026
| Field | Details |
|---|---|
| Patient Name | Mr. Mohan Das |
| Age | 52 years |
| Date of Admission | 06/07/2026 |
| IP/OP No | IP/2026/1009 |
| Weight (Kg) | 70 kg |
| Gender | Male |
| Unit | Pulmonology |
Reason for Admission/Visit C/O: Epilepsy on valproate; admitted for community-acquired pneumonia; started on trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis prophylaxis
Drug Related Problem(s) Identified: Drug-Drug Interaction - TMP-SMX + Warfarin. Trimethoprim-sulfamethoxazole stereoselectively inhibits the CYP2C9-mediated oxidative metabolism of S-warfarin, leading to its accumulation and enhanced anticoagulant effect. Patient is also on warfarin for DVT prophylaxis (post-immobility).
Reason(s) for Intervention: TMP-SMX is one of the listed agents that stereoselectively inhibits S-warfarin metabolism via CYP2C9. Without dose adjustment, the patient's INR may rise to dangerous levels within 3-5 days of starting TMP-SMX.
Suggestions Made: (1) Reduce warfarin dose by approximately 25% on initiation of TMP-SMX. (2) Check INR within 3-4 days of starting TMP-SMX. (3) Monitor closely for bleeding signs. (4) When TMP-SMX is discontinued, re-adjust warfarin dose upward as needed with INR monitoring. (5) If clinically appropriate, consider alternative antibiotic with lower interaction potential.
| Informed to HCP? | [X] Yes |
| Accepted? | [X] Yes |
| If No? Give Reasons: | - |
| Name & Signature of HCP | Dr. Ramesh Kulkarni, Pulmonologist |
| Name & Signature of Pharmacist | [Clinical Pharmacist] |
Preceptor's Name & Signature: _______________
FORM 10
Hospital: CSI HMH | Intervention Date: 13/07/2026
| Field | Details |
|---|---|
| Patient Name | Mrs. Geetha Subramaniam |
| Age | 60 years |
| Date of Admission | 11/07/2026 |
| IP/OP No | IP/2026/1010 |
| Weight (Kg) | 68 kg |
| Gender | Female |
| Unit | Hematology |
Reason for Admission/Visit C/O: Patient on warfarin for prosthetic heart valve (INR target 2.5-3.5); admitted with thromboembolic event; found to have started high-dose vitamin K supplements (multivitamin) on her own
Drug Related Problem(s) Identified: Drug-Drug/Drug-Nutrient Interaction - Warfarin + Vitamin K (pharmacodynamic antagonism). Vitamin K competitively antagonizes warfarin at the level of vitamin K epoxide reductase (VKORC1), directly reversing its anticoagulant effect by increasing synthesis of clotting factors II, VII, IX, and X. This is a direct pharmacodynamic interaction involving competitive antagonism of warfarin's mechanism of action.
Reason(s) for Intervention: Patient's INR dropped from 3.1 to 1.6 after self-initiating high-dose vitamin K-containing supplements 2 weeks ago, without informing her physician. Sub-therapeutic anticoagulation in a patient with a mechanical heart valve led to valve thrombosis and embolic stroke.
Suggestions Made: (1) Immediately discontinue high-dose vitamin K supplements. (2) Increase warfarin dose with daily INR monitoring until target range (2.5-3.5) is restored. (3) Administer therapeutic anticoagulation bridge (LMWH) until INR is stable. (4) Intensive patient counseling: patient must avoid self-medicating with vitamins/supplements without pharmacist/physician review. (5) Provide a written list of foods and supplements high in vitamin K to avoid or keep consistent in diet.
| Informed to HCP? | [X] Yes |
| Accepted? | [X] Yes |
| If No? Give Reasons: | - |
| Name & Signature of HCP | Dr. Vijay Anand, Hematologist |
| Name & Signature of Pharmacist | [Clinical Pharmacist] |
Preceptor's Name & Signature: _______________
Summary Table of All 10 Drug Interactions
| # | Drug 1 | Drug 2 | Interaction Type | Clinical Risk | Severity |
|---|---|---|---|---|---|
| 1 | Warfarin | Fluconazole | PK - CYP2C9 inhibition (S-warfarin) | Supratherapeutic INR, bleeding | Major |
| 2 | Metformin | Fluoxetine (SSRI) | PD - Enhanced hypoglycemia | Hypoglycemia | Moderate |
| 3 | Aspirin (low-dose) | Ibuprofen (NSAID) | PD - Competitive COX-1 antagonism | Loss of cardioprotection, re-MI | Major |
| 4 | Warfarin + Phenobarbital | Rifampin | PK - CYP enzyme induction | Sub-therapeutic warfarin; seizures | Major |
| 5 | Sertraline (SSRI) | Tramadol | PD - Serotonergic excess | Serotonin syndrome | Major |
| 6 | Enalapril (ACE-I) | Spironolactone | PD - Additive K+ retention | Life-threatening hyperkalemia | Major |
| 7 | Warfarin | Amiodarone | PK - CYP2C9/2C19 inhibition (both enantiomers) | Severe bleeding | Major |
| 8 | Levothyroxine | Cholestyramine | PK - Reduced GI absorption (binding) | Hypothyroidism relapse | Moderate |
| 9 | Warfarin | TMP-SMX | PK - CYP2C9 inhibition (S-warfarin) | Bleeding risk | Major |
| 10 | Warfarin | Vitamin K (supplement) | PD - Competitive antagonism at VKORC1 | Valve thrombosis, stroke | Major |
Sources: Drug interaction data sourced from Katzung's Basic and Clinical Pharmacology, 16th Edition (Drug Interactions chapter, pp. 963-965); Goodman & Gilman's Pharmacological Basis of Therapeutics; Harrison's Principles of Internal Medicine 22E; and Tintinalli's Emergency Medicine. All forms are illustrative examples designed for Farooqia College of Pharmacy clinical pharmacy training purposes.
This is a shared conversation. Sign in to Orris to start your own chat.